Overview
Clinical Meaning
GINA step therapy provides a systematic approach to asthma controller escalation and de escalation.
PMHNP
PMHNP
GINA step therapy provides a systematic approach to asthma controller escalation and de-escalation. Step 1-2: PRN low-dose ICS-formoterol (preferred) or daily low-dose ICS + SABA PRN. Step 3: low-dose ICS-LABA maintenance (budesonide-formoterol preferred for MART). Step 4: medium-dose ICS-LABA +/- LTRA or tiotropium. Step 5: high-dose ICS-LABA + tiotropium; consider anti-IgE (omalizumab), anti-IL5 (mepolizumab, benralizumab), anti-IL4R (dupilumab), or anti-TSLP (tezepelumab) biologics based on phenotype. The clinician prescribes initial therapy based on severity classification and adjusts every 2-3 months based on symptom control assessment (ACT or ACQ scores). Step-down is attempted after 3 months of well-controlled asthma, reducing ICS dose by 25-50% while monitoring.
Unlock full lesson + practice questions
4 more sections with scenarios, priorities, and review drills.
Final rapid review before practice
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this PMHNP pathway. You can still explore topic-filtered questions from the bank hubs below.